Active Ownership Capital proposes to the AGM of STADA Arzneimittel AG the complete replacement of the shareholder representatives in the Supervisory Board

DGAP-Media / 25.07.2016 / 19:58

- AOC proposes four new, independent candidates and supports two candidates
put forward by STADA

- The four new candidates have been chosen by a renowned executive search
firm in a professional process with participation of major shareholders

- Supervisory Board proposed by AOC possesses the necessary independence,
experience and expertise to enable STADA to develop positively long-term

Luxembourg/Bad Vilbel, July 25, 2016 - Active Ownership Capital, an
independent, partner-managed investment company, today announced that it
has submitted a supplementary motion as well as counter motions for the
agenda of the Annual General Meeting of STADA Arzneimittel AG (ISIN
DE0007251803) on August 26, 2016. The objective is to enable a
comprehensive restart of the company's corporate governance by completely
replacing the shareholder representatives in the Supervisory Board.

According to AOC's supplementary motion, the Supervisory Board members Dr.
Martin Abend and Carl Ferdinand Oetker shall be replaced. Instead of Dr.
Martin Abend, Dr. Eric Cornut (born 1957) stands for election. The
graduated lawyer was previously Chief Ethics, Compliance and Policy Officer
at Novartis AG. Before that, he held several managing position at Novartis,
amongst others he was Chief Commercial Officer, Head of Novartis' European
Pharma business and CEO of Novartis France, where he was also responsible
for Sandoz' French operations. He possesses comprehensive industrial
expertise as well as management expertise with a distinctive focus on good
corporate governance. It is AOC's opinion that after seven years as
Chairman of the Supervisory Board of STADA and a total of 13 years of being
a member of the Supervisory Board, Dr. Martin Abend is not suitable to lead
or support the necessary fresh start in the corporate governance of STADA.

Instead of Carl Ferdinand Oetker, Dr. Ursula Schütze-Kreilkamp (born 1959)
is proposed for election. Since 2012, she has been Head of Group HR
Development at DB Mobility Logistics AG and prior to this since 2006 she
has been e.g. Head of Executive Development at REWE-Group. The consultant
physician for gynecology and doctor for psychotherapy and psychosomatic
medicine has comprehensive healthcare-know-how. In the course of her 16
years working experience as a medical practitioner as well as in her
academic work, she has focused on Psychooncology/ Psychotraumatology, the
coping with distressing life situations and the coaching of managers. Dr.
Ursula Schütze-Kreilkamp is specialized on the composition of effective